Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year Low – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price reached a new 52-week low on Wednesday . The stock traded as low as $13.32 and last traded at $13.45, with a volume of 726407 shares changing hands. The stock had previously closed at $13.75.

Analyst Ratings Changes

KLRA has been the subject of a number of research analyst reports. Wall Street Zen downgraded Kailera Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings assumed coverage on Kailera Therapeutics in a research note on Friday, August 14th. They issued a “sell (d)” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Price Performance

The firm has a market capitalization of $1.74 billion and a price-to-earnings ratio of -0.00. The company’s fifty day moving average price is $17.53.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, equities research analysts forecast that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics during the second quarter worth approximately $24,233,000. Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Kailera Therapeutics during the second quarter worth $113,923,000. Wellington Management Group LLP purchased a new position in Kailera Therapeutics in the 2nd quarter valued at $64,308,000. Tidal Investments LLC acquired a new position in Kailera Therapeutics in the 2nd quarter valued at $309,000. Finally, Squarepoint Ops LLC acquired a new position in Kailera Therapeutics in the 2nd quarter valued at $993,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.